Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973229 · ClinicalTrials.gov registry record · Early Phase 1
Neuroendocrine Risk for PTSD in Women
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 250
- Enrollment target
NCT03973229 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 250 participants.
The verdict
NCT03973229, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase): 1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD 2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD 3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported) Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.
Interventions
- DRUG Estradiol patch
- OTHER Placebo patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2019-11-11 |
| Est. Completion | 2025-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973229
The ClinicalTrials.gov registry entry for NCT03973229 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estradiol patch is the first listed.
NCT03973229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03973229 about?
NCT03973229 is a clinical study titled "Neuroendocrine Risk for PTSD in Women". This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early f...
What is the current status of trial NCT03973229?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 250 participants. The study started on 2019-11-11. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT03973229?
The interventions under investigation include: Estradiol patch (DRUG), Placebo patch (OTHER).
Who is sponsoring clinical trial NCT03973229?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.